Wird geladen...
The safety of JAK-1 inhibitors
As efficacy and safety data emerge, differences between JAK inhibitor subclasses are appearing. JAK1 selective drugs, upadacitinib and filgotinib, have broadly come with the same overarching safety recommendations as other immunosuppressive drugs for RA: caution is needed regarding infection risk; m...
Gespeichert in:
| Veröffentlicht in: | Rheumatology (Oxford) |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Oxford University Press
2021
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8098103/ https://ncbi.nlm.nih.gov/pubmed/33950230 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rheumatology/keaa895 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|